Rudolph E. Tanzi, Ph.D.
Chairperson, Cure Alzheimer’s Fund Research Consortium
Joseph P. and Rose F. Kennedy Professor of Neurology
Harvard Medical School,
Director, Genetics and Aging Research Unit,
MassGeneral Institute for Neurodegenerative Disease
Department of Neurology
Massachusetts General Hospital
114 16th Street
Charletown, MA 02129
Timothy W. Armour
President and CEO
Cure Alzheimer’s Fund
34 Washington Street Suite 300
Wellesly Hills, MA 02481
The overarching goal of a national AD research strategy is to reach a cure most efficiently by accelerating studies aimed at identifying and characterizing all of the genes that influence susceptibility to AD, placing highest priority on those that will most readily lead to effective therapeutics for the treatment and prevention of AD.
Over the next decade, the influx of roughly 50 billion dollars into AD research should allow us by 2020 to identify all of the genes involved in AD susceptibility, and to arrive at a cure based largely on prevention.